Paul has over 30 years of experience in the global life sciences industry, with the past 20 years of his executive career focused on Clinical Diagnostics and innovative products to improve patients’ lives. He has held leadership positions within PredictImmune, Transgenomic, ZyGEM Corp., Life Technologies (now ThermoFisher), Guava Technologies and Cellomics, raising more than $70m in funding, creating global partnerships and increasing shareholder return. Paul has spent half of his career living and working in the USA running global businesses, which gives him a novel and unique outlook on the global industry; additionally he sits on a number of Boards as non-executive director (NED) for Life Science companies.
Diadem US Inc
Peter has a degree in Engineering and Management from Cambridge University and is a Chartered Accountant.
He has over 35 years in international business including as CFO of public companies in the medical diagnostics, pharmaceuticals, engineering, and chemical sectors and also has secured a successful exit for a PE backed analytical laboratories group. Most recently he has been CFO of two Cambridge based genomics start-ups.
Peter was until recently a non-executive director, Chairman of the Audit and Risk Committee, and member of the Remuneration and Nomination Committees for a listed healthcare business.
Diadem US Inc
Chief Medical Officer
A board-certified neurologist and a seasoned medication and device (including software as medical device) development expert, with more than 20 years of global experience in multiple therapy areas (including: neurology, psychiatry, immunology, infectious diseases, gastroenterology, women’s health, and rare diseases).
Served as Chief Medical Officer with several biotech companies and as a senior leader in clinical development and medical affairs in mid-size and large pharmaceutical companies, such as H. Lundbeck A/S, Shire Plc., Abbott Labs, Solvay Pharmaceuticals, and Teva Pharmaceutical industry.
With an extensive experience in clinical, medical, and regulatory strategy, multidisciplinary team leadership, portfolio management, clinical trial design and execution (early- and late-phase), IND / CTA submissions, regulatory briefings and meetings, NDA / MAH submissions, product launches, and market access preparations (in multiple geographies, including: the US, Europe, Japan, China, and Brazil).
Specializing in: target product-profile, clinical-development plans, protocol writing, value dossiers, scientific communications, patient-centric assessments and outcomes, real-world evidence generation, medication-device combinations, big-data analysis, digital tools development, and precision treatment-management.
Has taken an active part in public-private partnerships, pre-competitive collaborations and business alliances, and in a number of financing rounds (including IPO, NASDAQ listing, private placement and non-dilutional funding).
Head of external collaborations and grants
+15 years experience in CFO roles in various industries, in different economic context (high speed growth, consolidating, restructuring, etc) and of various size (startup, scale up and multinationals) around the globe (France, Italy, Mexico and China). Expertise in communicating with Leadership team, BoD and Shareholders and monitoring and managing daily cash and debt financing, in building FP&A & BI, in supervising local GAAPs (French, Chinese and Italian), IFRS and financial procedures, in designing governance and leading special projects (cross-border M&A, equity funding, etc).
Diadem US Inc
Ph.D., VP Operations & Development
Experienced manager with profound knowledge of life science sector. In 2009 she co-founded the company VisMederi srl and she was COO until 2016, serving clients such as Sanofi, Novartis, GSK, Takeda in vaccine immunogenicity evaluation and analytical assay validation.